8 results on '"Weissman, Yulia"'
Number of results to display per page
Search Results
2. Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study
- Author
-
Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Ruben, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, de Cueto, Marina, Oliver, Antonio, de Gopegui, Enrique Ruiz, Cano, Angela, Machuca, Isabel, Gozalo-Marguello, Monica, Martinez-Martinez, Luis, Gonzalez-Barbera, Eva M., Alfaro, Iris Gomez, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller–Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, and Yahav, Dafna
- Published
- 2022
- Full Text
- View/download PDF
3. Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study
- Author
-
Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Ruben, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, MacGowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Maurer, Susanna, Rodriguez-Bano, Jesus, Morales, Isabel, Oliver, Antonio, de Gopegui, Enrique Ruiz, Cano, Angela, Machuca, Isabel, Gozalo-Marguello, Monica, Martinez-Martinez, Luis, Gonzalez-Barbera, Eva M., Alfaro, Iris Gomez, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller-Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, and Yahav, Dafna
- Published
- 2020
- Full Text
- View/download PDF
4. Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study
- Author
-
Yahav, Dafna [0000-0003-3181-9791], Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Rubén, Rivera, Alba, Pulcini, Céline, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, Cueto, Marina de, Oliver, Antonio, Ruiz de Gopegui Bordes, Enrique, Cano, Ángela, Machuca, Isabel, Gozalo-Margüello, Mónica, Martínez-Martínez, Luis, González-Barbera, Eva M., Gómez Alfaro, Iris, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller-Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, Yahav, Dafna, Yahav, Dafna [0000-0003-3181-9791], Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Rubén, Rivera, Alba, Pulcini, Céline, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, Cueto, Marina de, Oliver, Antonio, Ruiz de Gopegui Bordes, Enrique, Cano, Ángela, Machuca, Isabel, Gozalo-Margüello, Mónica, Martínez-Martínez, Luis, González-Barbera, Eva M., Gómez Alfaro, Iris, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller-Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, and Yahav, Dafna
- Abstract
[Introduction] There is no consensus regarding optimal duration of antibiotic therapy for Pseudomonas aeruginosa bacteremia. We aimed to evaluate the impact of short antibiotic course., [Methods] We present a retrospective multicenter study including patients with P. aeruginosa bacteremia during 2009–2015. We evaluated outcomes of patients treated with short (6–10 days) versus long (11–15 days) antibiotic courses. The primary outcome was a composite of 30-day mortality or bacteremia recurrence and/or persistence. Univariate and inverse probability treatment-weighted (IPTW) adjusted multivariate analysis for the primary outcome was performed. To avoid immortal time bias, the landmark method was used., [Results] We included 657 patients; 273 received a short antibiotic course and 384 a long course. There was no significant difference in baseline characteristics of patients. The composite primary outcome occurred in 61/384 patients in the long-treatment group (16%) versus 32/273 in the short-treatment group (12%) (p = 0.131). Mortality accounted for 41/384 (11%) versus 25/273 (9%) of cases, respectively. Length of hospital stay was significantly shorter in the short group [median 13 days, interquartile range (IQR) 9–21 days, versus median 15 days, IQR 11–26 days, p = 0.002]. Ten patients in the long group discontinued antibiotic therapy owing to adverse events, compared with none in the short group. On univariate and multivariate analyses, duration of therapy was not associated with the primary outcome., [Conclusions] In this retrospective study, 6–10 days of antibiotic course for P. aeruginosa bacteremia were as effective as longer courses in terms of survival and recurrence. Shorter therapy was associated with reduced length of stay and less drug discontinuation.
- Published
- 2022
5. Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study
- Author
-
Babich, Tanya, primary, Naucler, Pontus, additional, Valik, John Karlsson, additional, Giske, Christian G, additional, Benito, Natividad, additional, Cardona, Ruben, additional, Rivera, Alba, additional, Pulcini, Celine, additional, Abdel Fattah, Manal, additional, Haquin, Justine, additional, MacGowan, Alasdair, additional, Grier, Sally, additional, Gibbs, Julie, additional, Chazan, Bibiana, additional, Yanovskay, Anna, additional, Ami, Ronen Ben, additional, Landes, Michal, additional, Nesher, Lior, additional, Zaidman-Shimshovitz, Adi, additional, McCarthy, Kate, additional, Paterson, David L, additional, Tacconelli, Evelina, additional, Buhl, Michael, additional, Mauer, Susanna, additional, Rodriguez-Bano, Jesus, additional, Morales, Isabel, additional, Oliver, Antonio, additional, Ruiz de Gopegui, Enrique, additional, Cano, Angela, additional, Machuca, Isabel, additional, Gozalo-Marguello, Monica, additional, Martinez, Luis Martinez, additional, Gonzalez-Barbera, Eva M, additional, Alfaro, Iris Gomez, additional, Salavert, Miguel, additional, Beovic, Bojana, additional, Saje, Andreja, additional, Mueller-Premru, Manica, additional, Pagani, Leonardo, additional, Vitrat, Virginie, additional, Kofteridis, Diamantis, additional, Zacharioudaki, Maria, additional, Maraki, Sofia, additional, Weissman, Yulia, additional, Paul, Mical, additional, Dickstein, Yaakov, additional, Leibovici, Leonard, additional, and Yahav, Dafna, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study
- Author
-
Babich, Tanya, primary, Naucler, Pontus, primary, Valik, John Karlsson, primary, Giske, Christian G, primary, Benito, Natividad, primary, Cardona, Ruben, primary, Rivera, Alba, primary, Pulcini, Celine, primary, Abdel Fattah, Manal, primary, Haquin, Justine, primary, Macgowan, Alasdair, primary, Grier, Sally, primary, Gibbs, Julie, primary, Chazan, Bibiana, primary, Yanovskay, Anna, primary, Ben Ami, Ronen, primary, Landes, Michal, primary, Nesher, Lior, primary, Zaidman-Shimshovitz, Adi, primary, McCarthy, Kate, primary, Paterson, David L, primary, Tacconelli, Evelina, primary, Buhl, Michael, primary, Mauer, Susanna, primary, Rodriguez-Bano, Jesus, primary, Morales, Isabel, primary, Oliver, Antonio, primary, Ruiz De Gopegui, Enrique, primary, Cano, Angela, primary, Machuca, Isabel, primary, Gozalo-Marguello, Monica, primary, Martinez Martinez, Luis, primary, Gonzalez-Barbera, Eva M, primary, Alfaro, Iris Gomez, primary, Salavert, Miguel, primary, Beovic, Bojana, primary, Saje, Andreja, primary, Mueller-Premru, Manica, primary, Pagani, Leonardo, primary, Vitrat, Virginie, primary, Kofteridis, Diamantis, primary, Zacharioudaki, Maria, primary, Maraki, Sofia, primary, Weissman, Yulia, primary, Paul, Mical, primary, Dickstein, Yaakov, primary, Leibovici, Leonard, primary, and Yahav, Dafna, primary
- Published
- 2019
- Full Text
- View/download PDF
7. Duration of Treatment for Pseudomonas aeruginosaBacteremia: a Retrospective Study
- Author
-
Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Ruben, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, de Cueto, Marina, Oliver, Antonio, de Gopegui, Enrique Ruiz, Cano, Angela, Machuca, Isabel, Gozalo-Marguello, Monica, Martinez-Martinez, Luis, Gonzalez-Barbera, Eva M., Alfaro, Iris Gomez, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller–Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, and Yahav, Dafna
- Abstract
Introduction: There is no consensus regarding optimal duration of antibiotic therapy for Pseudomonas aeruginosabacteremia. We aimed to evaluate the impact of short antibiotic course. Methods: We present a retrospective multicenter study including patients with P. aeruginosabacteremia during 2009–2015. We evaluated outcomes of patients treated with short (6–10 days) versus long (11–15 days) antibiotic courses. The primary outcome was a composite of 30-day mortality or bacteremia recurrence and/or persistence. Univariate and inverse probability treatment-weighted (IPTW) adjusted multivariate analysis for the primary outcome was performed. To avoid immortal time bias, the landmark method was used. Results: We included 657 patients; 273 received a short antibiotic course and 384 a long course. There was no significant difference in baseline characteristics of patients. The composite primary outcome occurred in 61/384 patients in the long-treatment group (16%) versus 32/273 in the short-treatment group (12%) (p= 0.131). Mortality accounted for 41/384 (11%) versus 25/273 (9%) of cases, respectively. Length of hospital stay was significantly shorter in the short group [median 13 days, interquartile range (IQR) 9–21 days, versus median 15 days, IQR 11–26 days, p= 0.002]. Ten patients in the long group discontinued antibiotic therapy owing to adverse events, compared with none in the short group. On univariate and multivariate analyses, duration of therapy was not associated with the primary outcome. Conclusions: In this retrospective study, 6–10 days of antibiotic course for P. aeruginosabacteremia were as effective as longer courses in terms of survival and recurrence. Shorter therapy was associated with reduced length of stay and less drug discontinuation.
- Published
- 2022
- Full Text
- View/download PDF
8. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
- Author
-
Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Abdel Fattah M, Haquin J, Macgowan A, Grier S, Gibbs J, Chazan B, Yanovskay A, Ben Ami R, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, Buhl M, Mauer S, Rodriguez-Bano J, Morales I, Oliver A, Ruiz De Gopegui E, Cano A, Machuca I, Gozalo-Marguello M, Martinez Martinez L, Gonzalez-Barbera EM, Alfaro IG, Salavert M, Beovic B, Saje A, Mueller-Premru M, Pagani L, Vitrat V, Kofteridis D, Zacharioudaki M, Maraki S, Weissman Y, Paul M, Dickstein Y, Leibovici L, and Yahav D
- Subjects
- Anti-Bacterial Agents therapeutic use, Carbapenems therapeutic use, Ceftazidime therapeutic use, Humans, Microbial Sensitivity Tests, Penicillanic Acid therapeutic use, Piperacillin therapeutic use, Retrospective Studies, Pseudomonas Infections drug therapy, Pseudomonas aeruginosa
- Abstract
Background: The optimal antibiotic regimen for Pseudomonas aeruginosa bacteremia is controversial. Although β-lactam monotherapy is common, data to guide the choice between antibiotics are scarce. We aimed to compare ceftazidime, carbapenems, and piperacillin-tazobactam as definitive monotherapy., Methods: A multinational retrospective study (9 countries, 25 centers) including 767 hospitalized patients with P. aeruginosa bacteremia treated with β-lactam monotherapy during 2009-2015. The primary outcome was 30-day all-cause mortality. Univariate and multivariate, including propensity-adjusted, analyses were conducted introducing monotherapy type as an independent variable., Results: Thirty-day mortality was 37/213 (17.4%), 42/210 (20%), and 55/344 (16%) in the ceftazidime, carbapenem, and piperacillin-tazobactam groups, respectively. Type of monotherapy was not significantly associated with mortality in either univariate, multivariate, or propensity-adjusted analyses (odds ratio [OR], 1.14; 95% confidence interval [CI], 0.52-2.46, for ceftazidime; OR, 1.3; 95% CI, 0.67-2.51, for piperacillin-tazobactam, with carbapenems as reference in propensity adjusted multivariate analysis; 542 patients). No significant difference between antibiotics was demonstrated for clinical failure, microbiological failure, or adverse events. Isolation of P. aeruginosa with new resistance to antipseudomonal drugs was significantly more frequent with carbapenems (36/206 [17.5%]) versus ceftazidime (25/201 [12.4%]) and piperacillin-tazobactam (28/332 [8.4%] (P = .007)., Conclusions: No significant difference in mortality, clinical, and microbiological outcomes or adverse events was demonstrated between ceftazidime, carbapenems, and piperacillin-tazobactam as definitive treatment of P. aeruginosa bacteremia. Higher rates of resistant P. aeruginosa after patients were treated with carbapenems, along with the general preference for carbapenem-sparing regimens, suggests using ceftazidime or piperacillin-tazobactam for treating susceptible infection., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.